Title: Clinical Characteristics and Treatment Outcomes of Primary Malignant Melanoma of
Esophagus: A Single Center Experience
Version: 1 Date: 24 Dec 2021
Reviewer's report:
I reviewed the manuscript regarding mucosal melanoma of esophagus with certain interests.
Although the number of the patients in the present study was small, I think it is worth being
recorded considering its rarity. I have particular interests in two topics; one is a clinical impact
of immune-checkpoint inhibitors for PMME, and the other is the prognostic factors of PMME.
The followings are my minor comments.
1. Please consider adding Kaplan-Meier curves between those who received immune-checkpoint
inhibitors (regardless of adjuvant or metastatic setting) and those who did not.
2. There are only a few articles regarding immune-checkpoint inhibitors for PMME, but
several studies of mucosal melanoma including PMME have been published. Please update
the references by adding recent articles regarding immune-checkpoint inhibitors for mucosal
melanoma.
3. You demonstrated tumor morphology of mass-forming / infiltrative can be a prognostic factor
of PMME. This may be attributed to the tumor thickness, which is a main component of T
category in cutaneous melanoma. Please add the tumor morphology status (mass-forming /
infiltrative) in Table 2 and 3, and if possible, consider adding tumor thickness in addition to
tumor size.
4. In Figure 2B to D, please add the number of the patients in each cohort.
5. In Figure 2C, please consider dividing ‘N+ or M1’ cohort into each ‘N+’ or ‘M1’ cohort.
6. If available, please add BRAF and PD-L1 status.
Title: Clinical Characteristics and Treatment Outcomes of Primary Malignant Melanoma of
Esophagus: A Single Center Experience
Version: 1 Date: 24 Dec 2021
Reviewer's report:
I reviewed the manuscript regarding mucosal melanoma of esophagus with certain interests.
Although the number of the patients in the present study was small, I think it is worth being
recorded considering its rarity. I have particular interests in two topics; one is a clinical impact
of immune-checkpoint inhibitors for PMME, and the other is the prognostic factors of PMME.
The followings are my minor comments.
1. Please consider adding Kaplan-Meier curves between those who received immune-checkpoint
inhibitors (regardless of adjuvant or metastatic setting) and those who did not.
2. There are only a few articles regarding immune-checkpoint inhibitors for PMME, but
several studies of mucosal melanoma including PMME have been published. Please update
the references by adding recent articles regarding immune-checkpoint inhibitors for mucosal
melanoma.
3. You demonstrated tumor morphology of mass-forming / infiltrative can be a prognostic factor
of PMME. This may be attributed to the tumor thickness, which is a main component of T
category in cutaneous melanoma. Please add the tumor morphology status (mass-forming /
infiltrative) in Table 2 and 3, and if possible, consider adding tumor thickness in addition to
tumor size.
4. In Figure 2B to D, please add the number of the patients in each cohort.
5. In Figure 2C, please consider dividing ‘N+ or M1’ cohort into each ‘N+’ or ‘M1’ cohort.
6. If available, please add BRAF and PD-L1 status.
Please review this paper.
user
Title: Clinical Characteristics and Treatment Outcomes of Primary Malignant Melanoma of
Esophagus: A Single Center Experience
Version: 1 Date: 24 Dec 2021
Reviewer's report:
I reviewed the manuscript regarding mucosal melanoma of esophagus with certain interests.
Although the number of the patients in the present study was small, I think it is worth being
recorded considering its rarity. I have particular interests in two topics; one is a clinical impact
of immune-checkpoint inhibitors for PMME, and the other is the prognostic factors of PMME.
The followings are my minor comments.
1. Please consider adding Kaplan-Meier curves between those who received immune-checkpoint
inhibitors (regardless of adjuvant or metastatic setting) and those who did not.
2. There are only a few articles regarding immune-checkpoint inhibitors for PMME, but
several studies of mucosal melanoma including PMME have been published. Please update
the references by adding recent articles regarding immune-checkpoint inhibitors for mucosal
melanoma.
3. You demonstrated tumor morphology of mass-forming / infiltrative can be a prognostic factor
of PMME. This may be attributed to the tumor thickness, which is a main component of T
category in cutaneous melanoma. Please add the tumor morphology status (mass-forming /
infiltrative) in Table 2 and 3, and if possible, consider adding tumor thickness in addition to
tumor size.
4. In Figure 2B to D, please add the number of the patients in each cohort.
5. In Figure 2C, please consider dividing ‘N+ or M1’ cohort into each ‘N+’ or ‘M1’ cohort.
6. If available, please add BRAF and PD-L1 status.
assistant